This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (65)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Health Policy  • Alert me on articles by topic

Hamilton Moses III, MD; E. Ray Dorsey, MD, MBA; David H. M. Matheson, JD, MBA; Samuel O. Thier, MD

JAMA. 2005;294:1333-1342.

Context  Public and private financial support of biomedical research have increased over the past decade. Few comprehensive analyses of the sources and uses of funds are available. This results in inadequate information on which to base investment decisions because not all sources allow equal latitude to explore hypotheses having scientific or clinical importance and creates a barrier to judging the value of research to society.

Objective  To quantify funding trends from 1994 to 2004 of basic, translational, and clinical biomedical research by principal sponsors based in the United States.

Design  Publicly available data were compiled for the federal, state, and local governments; foundations; charities; universities; and industry. Proprietary (by subscription but openly available) databases were used to supplement public sources.

Main Outcome Measures  Total actual research spending, growth rates, and type of research with inflation adjustment.

Results  Biomedical research funding increased from $37.1 billion in 1994 to $94.3 billion in 2003 and doubled when adjusted for inflation. Principal research sponsors in 2003 were industry (57%) and the National Institutes of Health (28%). Relative proportions from all public and private sources did not change. Industry sponsorship of clinical trials increased from $4.0 to $14.2 billion (in real terms) while federal proportions devoted to basic and applied research were unchanged. The United States spent an estimated 5.6% of its total health expenditures on biomedical research, more than any other country, but less than 0.1% for health services research. From an economic perspective, biotechnology and medical device companies were most productive, as measured by new diagnostic and therapeutic devices per dollar of research and development cost. Productivity declined for new pharmaceuticals.

Conclusions  Enhancing research productivity and evaluation of benefit are pressing challenges, requiring (1) more effective translation of basic scientific knowledge to clinical application; (2) critical appraisal of rapidly moving scientific areas to guide investment where clinical need is greatest, not only where commercial opportunity is currently perceived; and (3) more specific information about sources and uses of research funds than is generally available to allow informed investment decisions. Responsibility falls on industry, government, and foundations to bring these changes about with a longer-term view of research value.

Author Affiliations: The Alerion Institute, North Garden, Va (Dr Moses); The Boston Consulting Group, Bethesda, Md (Dr Moses and Mr Matheson); Department of Medicine and Health Policy, Massachusetts General Hospital and Harvard Medical School, Boston (Dr Thier); Department of Neurology, University of Rochester Medical Center, Rochester, NY (Dr Dorsey). Dr Dorsey performed most of his work while at the Hospital of the University of Pennsylvania.

RELATED LETTERS

Funding for Biomedical Research
Michael Seid and Elizabeth A. McGlynn
JAMA. 2006;295(9):1000.
EXTRACT | FULL TEXT  

Funding for Biomedical Research—Reply
Hamilton Moses, III, E. Ray Dorsey, David H. M. Matheson, and Samuel O. Thier
JAMA. 2006;295(9):1000-1001.
EXTRACT | FULL TEXT  

Funding for Biomedical Research
Joel Kupersmith and Jonathan Brian Perlin
JAMA. 2006;295(9):999-1000.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Outcomes Research: Generating Evidence for Best Practice and Policies
Krumholz
Circulation 2008;118:309-318.
FULL TEXT  

The "3T's" Road Map to Transform US Health Care: The "How" of High-Quality Care
Dougherty and Conway
JAMA 2008;299:2319-2321.
FULL TEXT  

Patients' priorities for health research: focus group study of patients with chronic kidney disease
Tong et al.
Nephrol Dial Transplant 2008;0:gfn207v1-gfn207.
ABSTRACT | FULL TEXT  

Impact of the National Institutes of Health on Radiology Research
Itagaki
Radiology 2008;247:213-219.
ABSTRACT | FULL TEXT  

From Waste to Value in Health Care
Boat et al.
JAMA 2008;299:568-571.
FULL TEXT  

Sensible approaches for reducing clinical trial costs
Eisenstein et al.
Clin Trials 2008;5:75-84.
ABSTRACT  

The Meaning of Translational Research and Why It Matters
Woolf
JAMA 2008;299:211-213.
FULL TEXT  

Medical Device Regulations and Testing for Toxicologic Pathologists
Schuh
Toxicol Pathol 2008;36:63-69.
ABSTRACT | FULL TEXT  

Leveraging University Research to Advance Global Health
Chokshi and Rajkumar
JAMA 2007;298:1934-1936.
FULL TEXT  

The Sound and the Fury: Financial Conflicts of Interest in Oncology
Djulbegovic et al.
JCO 2007;25:3567-3569.
FULL TEXT  

American College Of Medical Quality Annual Meeting: Summary Report and Key Messages
Clarke
American Journal of Medical Quality 2007;22:289-295.
 

Use and Perceptions of Clinical Practice Guidelines by Internal Medicine Physicians
Shea et al.
American Journal of Medical Quality 2007;22:170-176.
ABSTRACT  

The cycle of quality as a model for improving health outcomes in the treatment of hypertension
Califf
Eur Heart J Suppl 2007;9:B8-B12.
ABSTRACT | FULL TEXT  

The Legal and Ethical Issues Surrounding Financial Conflict of Interest in Orthopaedic Research
Okike and Kocher
JBJS 2007;89:910-913.
FULL TEXT  

Giving Everyone the Health of the Educated: An Examination of Whether Social Change Would Save More Lives Than Medical Advances
Woolf et al.
Am. J. Public Health 2007;97:679-683.
ABSTRACT | FULL TEXT  

Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics
Califf et al.
Health Aff (Millwood) 2007;26:62-74.
ABSTRACT | FULL TEXT  

Measuring Performance For Treating Heart Attacks And Heart Failure: The Case For Outcomes Measurement
Krumholz et al.
Health Aff (Millwood) 2007;26:75-85.
ABSTRACT | FULL TEXT  

An Introduction to Foundation and Industry-Sponsored Research: Practical and Ethical Considerations
Margolin et al.
ASH Education Book 2007;2007:498-503.
ABSTRACT | FULL TEXT  

Late Ischemic Events After Clopidogrel Cessation Following Drug-Eluting Stenting: Should We Be Worried?
Harrington and Califf
J Am Coll Cardiol 2006;48:2592-2595.
FULL TEXT  

Clinical trials bureaucracy: unintended consequences of well-intentioned policy
Califf
Clin Trials 2006;3:496-502.
ABSTRACT  

Patents and data-sharing in public science
Eisenberg
Ind Corp Change 2006;15:1013-1031.
ABSTRACT | FULL TEXT  

The Influence of Money on Medical Science
DeAngelis
JAMA 2006;296:996-998.
FULL TEXT  

The Agency for Healthcare Research and Quality's National Healthcare Quality and Disparities Reports: Action Agendas for the Nation.
McNeill et al.
American Journal of Medical Quality 2006;21:206-209.
 

News from APTA
ptjournal 2006;86:754-755.
FULL TEXT  

Funding for Biomedical Research
Seid and McGlynn
JAMA 2006;295:1000-1000.
FULL TEXT  

Funding for Biomedical Research
Kupersmith and Perlin
JAMA 2006;295:999-1000.
FULL TEXT  

What's new in the other general journals
Tonks
BMJ 2005;331:721-722.
FULL TEXT  

Medical Research--State of the Science
Fontanarosa et al.
JAMA 2005;294:1424-1425.
FULL TEXT